Novità scientifiche — 20 Settembre 2026
Aggiornamenti scientifici verificati da MBC. Questa pagina contiene esclusivamente elementi acquisiti da fonti documentali tracciabili dopo il radar scientifico giornaliero. L’AI può indicare termini da controllare, ma il suo testo non viene pubblicato come fonte e non determina conclusioni cliniche.
Le informazioni sono presentate a fini documentali e non costituiscono una raccomandazione terapeutica, una previsione di efficacia o una valutazione di idoneità individuale.
Nuova documentazione
- CD24 interacts with EDN1 to activate NFκB signaling driving triple-negative breast cancer tumor progression and paclitaxel resistance · Settembre 1, 2026
DOI: 10.1016/j.bbadis.2026.168455
Fonte documentale originale ↗ - Vignette-Based Estimation of Utilities in Patients With Metastatic Triple-Negative Breast Cancer in Japan · Novembre 1, 2026
DOI: 10.1016/j.vhri.2026.101619
Fonte documentale originale ↗ - Engineered α9-nAChR-targeting antibodies attenuate nicotine-enhanced triple-negative breast cancer progression and exhibit favorable short-term tolerability in cynomolgus macaques · Marzo 1, 2027
DOI: 10.1016/j.biomaterials.2026.124638
Fonte documentale originale ↗ - Corrigendum to “Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance” [Phytomedicine 154 (2026) 158016] · Novembre 1, 2026
DOI: 10.1016/j.phymed.2026.158463
Fonte documentale originale ↗ - ALYREF enhances breast cancer progression by regulating EZH2 · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e37749
Fonte documentale originale ↗ - Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38193
Fonte documentale originale ↗ - HI-Net: A novel histopathologic image segmentation model for metastatic breast cancer via lightweight dataset construction · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38410
Fonte documentale originale ↗ - Invasive Lobular Carcinoma with Gastric Metastasis Mimicking Linitis Plastica as the First Presentation: A Case Report · Aprile 4, 2026
DOI: 10.4103/ejcrp.ejcrp-d-25-00048
Fonte documentale originale ↗ - 16α-Hydroxydehydrotrametenolic acid attenuates MDA-MB-231 triple-negative breast cancer xenograft growth and modulates integrin β1/c-Met signaling and glycolytic metabolism · Novembre 1, 2026
DOI: 10.1016/j.phymed.2026.158731
Fonte documentale originale ↗ - Depolymerized fucoidan derivatives anti-migratory activity, driven by structure-controlled uptake, overrides heparanase in breast cancer cells · Ottobre 1, 2026
DOI: 10.1016/j.biopha.2026.119895
Fonte documentale originale ↗ - Structure-based Analysis of Immunohistochemical Expression of P53 and BCL2 in Breast Cancer · Settembre 1, 2026
DOI: 10.1016/j.tice.2026.103961
Fonte documentale originale ↗ - Novel Pseudomonas putida-derived nanoliposomes enhance the inhibition of MCF-7 breast cancer cells by superb intracellular uptake of doxorubicin · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38337
Fonte documentale originale ↗ - Leveraging MRI radiomics signature for predicting the diagnosis of CXCL9 in breast cancer · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38640
Fonte documentale originale ↗ - Hybrid ensemble deep learning model for advancing breast cancer detection and classification in clinical applications · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38374
Fonte documentale originale ↗ - Targeting paraoxonase-2 overcomes chemoresistance in triple-negative breast cancer cells by inducing extensive metabolic and molecular remodeling · Novembre 1, 2026
DOI: 10.1016/j.vibspec.2026.103961
Fonte documentale originale ↗
Farmaci e molecole
- Prognostic Value of Baseline Metabolic Tumor Volume on [¹⁸F]FDG PET/CT in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors · Settembre 1, 2026
DOI: 10.1016/j.clbc.2026.09.009
Fonte documentale originale ↗ - Knowledge discovery of patients reviews on breast cancer drugs: Segmentation of side effects using machine learning techniques · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38563
Fonte documentale originale ↗ - Identification of a PANoptosis-related prognostic model in triple-negative breast cancer, from risk assessment, immunotherapy, to personalized treatment · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38732
Fonte documentale originale ↗ - CaPaMoE: A clinical-aware pathology mixture-of-experts framework for predicting Neoadjuvant chemotherapy response in breast cancer · Settembre 1, 2026
DOI: 10.1016/j.jvcir.2026.104976
Fonte documentale originale ↗ - Prevalence and Determinants of Depression, Anxiety, and Quality of Life in Patients With Breast Cancer in Saudi Arabia: A Focus on Adjuvant Pharmacotherapy · Settembre 1, 2026
DOI: 10.1002/cam4.72288
Fonte documentale originale ↗
Trial e studi clinici
- Impact of Time-restricted Eating on Endothelial Function in Breast Cancer Survivors · Ottobre 1, 2026
DOI: 10.1016/j.jand.2026.156733
Fonte documentale originale ↗ - Amplifying sonodynamic–immunotherapy of breast cancer via a cuproptosis-inducing multifunctional nanozyme · Gennaio 1, 2027
DOI: 10.1016/j.colsurfa.2026.141690
Fonte documentale originale ↗ - Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial · Maggio 6, 2026
NCT: NCT03990896
Fonte documentale originale ↗ - A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer · Giugno 17, 2026
NCT: NCT07653893
Fonte documentale originale ↗ - Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer · Maggio 20, 2026
NCT: NCT06860815
Fonte documentale originale ↗ - A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) · Agosto 21, 2026
NCT: NCT07067138
Fonte documentale originale ↗ - Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · Agosto 18, 2026
NCT: NCT07391774
Fonte documentale originale ↗ - Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer · Agosto 14, 2026
NCT: NCT06518057
Fonte documentale originale ↗ - FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer · Agosto 12, 2026
NCT: NCT05304962
Fonte documentale originale ↗ - Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer · Agosto 12, 2026
NCT: NCT06525766
Fonte documentale originale ↗ - A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer. · Agosto 4, 2026
NCT: NCT07743944
Fonte documentale originale ↗ - Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis · Aprile 20, 2026
NCT: NCT06374459
Fonte documentale originale ↗ - S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer · Aprile 2, 2026
NCT: NCT03723928
Fonte documentale originale ↗ - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer · Settembre 4, 2026
NCT: NCT06062498
Fonte documentale originale ↗ - Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer · Agosto 18, 2026
NCT: NCT06993506
Fonte documentale originale ↗ - A Study of HLD-0117 in Patients With Metastatic Breast Cancer · Agosto 17, 2026
NCT: NCT07524855
Fonte documentale originale ↗ - A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer · Agosto 14, 2026
NCT: NCT07766018
Fonte documentale originale ↗ - A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) · Agosto 10, 2026
NCT: NCT06926868
Fonte documentale originale ↗ - AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. · Agosto 6, 2026
NCT: NCT02102165
Fonte documentale originale ↗ - Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Luglio 31, 2026
NCT: NCT07340541
Fonte documentale originale ↗ - FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer · Luglio 21, 2026
NCT: NCT04174352
Fonte documentale originale ↗
Biomarcatori e ricerca
- Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38221
Fonte documentale originale ↗ - Sensitive HER2 detection in breast cancer cells using 3D-printed carbon (CB/CNT) and pencil graphite electrochemical aptasensor platforms · Settembre 1, 2026
DOI: 10.1016/j.microc.2026.119755
Fonte documentale originale ↗ - The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study · Ottobre 1, 2024
DOI: 10.1016/j.heliyon.2024.e38147
Fonte documentale originale ↗